Protein / target

Breast cancer type 2 susceptibility protein

BRCA2P51587
UniProt: P51587
12
Research papers

Protein at a glance

Research activity

Emerging research

12 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Research activity

12 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.3,208 cites

Colaprico A · Nucleic acids research · 2016

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.1,295 cites

Kaufman B · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration.530 cites

Abida W · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020

Triple‑negative breast cancer therapy: Current and future perspectives (Review).351 cites

Won KA · International journal of oncology · 2020

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.282 cites

Kim H · Nature communications · 2020

Recent

Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms.

Jain A · Oncogene · 2025

Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Attard G · Nature medicine · 2025

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline.

Al Sukhun S · JCO global oncology · 2024

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in &lt;i&gt;BRCA1&lt;/i&gt; and/or &lt;i&gt;BRCA2&lt;/i&gt; in the PROfound Trial.

Mateo J · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.

Fallah J · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024

Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants.

Sahu S · PLoS genetics · 2023

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.

Chen KT · The oncologist · 2023

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration.

Abida W · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020

Triple‑negative breast cancer therapy: Current and future perspectives (Review).

Won KA · International journal of oncology · 2020

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.

Kim H · Nature communications · 2020

Europe PMC papers linked directly to this protein.